Leaps by Bayer
CVC
Active
Berlin, Germany
78
55M
52
8.67
12
0.33
1
- Areas of investment
Summary
Leaps by Bayer appeared to be the Corporate Investor, which was created in 2015. The main department of described Corporate Investor is located in the Leverkusen. The company was established in Europe in Germany.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Leaps by Bayer, startups are often financed by Longwood Founders Fund, Ipsen, Agent Capital. The meaningful sponsors for the fund in investment in the same round are Longwood Founders Fund, Ipsen, Agent Capital. In the next rounds fund is usually obtained by Longwood Founders Fund, Ipsen, Agent Capital.
Besides, a startup needs to be aged 1 and less years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Century Therapeutics, Pyxis Oncology, Pyxis Oncology Among the most popular fund investment industries, there are Therapeutics, Pharmaceutical. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in a number of founders of portfolio startups.
The high activity for fund was in 2019. The fund is constantly included in 2-6 investment rounds annually. The usual things for fund are deals in the range of 50 - 100 millions dollars. Speaking about the real fund results, this Corporate Investor is 47 percentage points more often commits exit comparing to other organizations.
Investor highlights
- Industry focus
- Stage focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund size
- EUR 1300000000
- Fund raised date
- 2022-04-03
Analytics
- Total investments
- 78
- Lead investments
- 12
- Exits
- 1
- Rounds per year
- 8.67
- Follow on index
- 0.33
- Investments by industry
- Biotechnology (50)
- Health Care (38)
- Therapeutics (19)
- Agriculture (17)
- Medical (15) Show 42 more
- Investments by region
-
- United States (68)
- United Kingdom (2)
- Germany (1)
- Canada (2)
- Kenya (2) Show 2 more
- Peak activity year
- 2021
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Avg. valuation at time of investment
- 93M
- Group Appearance index
- 0.95
- Avg. company exit year
- 8
- Avg. multiplicator
- 4.06
- Strategy success index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Deka Biosciences | 01 Jan 2022 | Biotechnology, Health Care | Early Stage Venture | 21M | United States, District of Columbia, Washington |
| Summer Health | 23 Apr 2024 | Home Health Care | Early Stage Venture | 11M | United States, New York, New York |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.